Policy
Policy
Government Funding & Appropriations
Background
Public investment in research conducted by the National Institutes of Health (NIH) underlies discoveries in personalized medicine that ultimately provide better treatments to patients. Investment in the U.S. Food and Drug Administration (FDA), which serves as the gateway for many personalized medicine products entering the market, is equally important to facilitate patient access to personalized medicine. Consistent and robust funding for both agencies thus ensures personalized medicine will deliver on its promise for patients and the U.S. health system.
2023
Testimony Submitted to U.S. House of Representatives on FY 2024 Appropriations for NIH
- PMC outside witness testimony (PDF)
March 23, 2023
PMC Co-Signs Ad Hoc Group for Medical Research Letter Advocating for at Least $50.924 Billion for FY 2024 NIH Base Budget
- Ad Hoc Group for Medical Research letter (PDF)
March 14, 2023
2022
PMC Co-Signs Ad Hoc Group for Medical Research Letter Urging Swift Passage of at Least $47.5 Billion for FY 2023 NIH Base Budget
- Ad Hoc Group for Medical Research letter (PDF)
November 8, 2022
Testimony Submitted to U.S. House of Representatives on FY 2023 Appropriations for FDA
- PMC outside witness testimony (PDF)
May 31, 2022
Testimony Submitted to U.S. House of Representatives on FY 2023 Appropriations for NIH
- PMC outside witness testimony (PDF)
May 26, 2022
Testimony Submitted to U.S. Senate on FY 2023 Appropriations for NIH
- PMC outside witness testimony (PDF)
May 11, 2022
Testimony Submitted to U.S. Senate on FY 2023 Appropriations for FDA
- PMC outside witness testimony (PDF)
May 6, 2022
PMC Co-Signs Ad Hoc Group for Medical Research Letter Urging Appropriations of at Least $49.048 Billion for NIH Base Budget in FY 2023
- Ad Hoc Group for Medical Research letter (PDF)
May 10, 2022
2021
PMC Co-Signs Ad Hoc Group for Medical Research Letter Urging Swift Passage of FY 2022 Appropriations for NIH
- Ad Hoc Group for Medical Research letter
November 15, 2021
Testimony Submitted to U.S. Senate on FY 2022 Appropriations for NIH
- PMC Outside Witness Testimony (PDF)
June 2021
Testimony Submitted to U.S. House of Representatives on FY 2022 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
May 2021
Testimony Submitted to U.S. Senate on FY 2022 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
May 2021
Testimony Submitted to U.S. House of Representatives on FY 2022 Appropriations for NIH
- PMC Outside Witness Testimony (PDF)
May 2021
Ad Hoc Group for Medical Research Statement on FY 2022 Funding for the U.S. National Institutes of Health (Co-signed by PMC and 360 Other Institutions)
2020
Ad Hoc Group for Medical Research Letter to President-elect Joe Biden (Co-signed by PMC and 348 Other Institutions)
- Ad Hoc Group for Medical Research letter (PDF)
December 2020
Testimony Submitted to U.S. Senate on FY 2021 Appropriations for NIH
- PMC Outside Witness Testimony (PDF)
May 2020
Testimony Submitted to U.S. Senate on FY 2021 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
April 2020
Testimony Submitted to U.S. House of Representatives on FY 2021 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
March 2020
Testimony Submitted to U.S. House of Representatives on FY 2021 Appropriations for NIH
- PMC Outside Witness Testimony (PDF)
March 2020
2019
Testimony Submitted to U.S. Senate on FY 2020 Appropriations for NIH
Testimony Submitted to U.S. Senate on FY 2020 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
April 2019
Testimony Submitted to U.S. House of Representatives on FY 2020 Appropriations for NIH
- PMC Outside Witness Testimony (PDF)
April 2019
Testimony Submitted to U.S. House of Representatives on FY 2020 Appropriations for FDA
- PMC Outside Witness Testimony (PDF)
April 2019
Recommended Budget for the U.S. National Institutes of Health in 2020
Impact of Partial Government Shutdown (Dec. 22 - Jan. 28) on the U.S. Food and Drug Administration (FDA)
2018
In February of 2018, U.S. President Donald Trump proposed a significant increase to the budget for the U.S. Food and Drug Administration (FDA), which the Coalition applauded. However, even though Congress had recently voted to approve an increase of about $2 billion to the National Institutes of Health (NIH)’s budget from FY 2017, the President’s proposal allocated an amount to NIH that was roughly equivalent to FY 2017 funding levels. Advancement in personalized medicine depends on the strength of both agencies.
PMC advocated for robust funding for the NIH and FDA through outside witness testimonies submitted to subcommittees of the U.S. House and Senate Appropriations Committee. To align its members in advocating for NIH and FDA funding, PMC also disseminated talking points to its members.
- » Outside Witness Testimony on FY 2019 Appropriations for NIH Submitted to U.S. Senate Labor, Health and Human Services, Education and Related Agencies Appropriations Subcommittee
May 2018 - » Outside Witness Testimony on FY 2019 Appropriations for NIH Submitted to U.S. House Labor, Health and Human Services, Education and Related Agencies Appropriations Subcommittee
April 2018 - » Outside Witness Testimony on FY 2019 Appropriations for FDA Submitted to U.S. House Agriculture, Rural Development, Food and Drug Administration, & Related Agencies Appropriations Subcommittee
April 2018
- » Outside Witness Testimony on FY 2019 Appropriations for FDA Submitted to U.S. Senate Agriculture, Rural Development, Food and Drug Administration, & Related Agencies Appropriations Subcommittee
March 2018 - » Talking Points: FY 2019 Appropriations for the NIH and FDA
March 2018
2017
In May of 2017, U.S. President Donald Trump proposed an 18 percent cut to the National Institutes of Health (NIH)'s 2018 budget for biomedical research.
PMC remains committed to consistent and sufficient funding for NIH's work, which provides a foundation for innovation in personalized medicine. The Coalition called on the U.S. Congress to reject the President's proposed cut to NIH's budget.